Chapter 19
Role of Innate Immune Dysregulation in Diabetic Heart Failure
Betsy B. Dokken,
Paul F. McDonagh,
Betsy B. Dokken
Search for more papers by this authorPaul F. McDonagh
Search for more papers by this authorBetsy B. Dokken,
Paul F. McDonagh,
Betsy B. Dokken
Search for more papers by this authorPaul F. McDonagh
Search for more papers by this authorBook Editor(s):Ronald Ross Watson,
Douglas F. Larson,
Ronald Ross Watson
Department of Nutritional Sciences, The University of Arizona; and Sarver Heart Center, College of Medicine, The University of Arizona
Division of Health Promotion Sciences, Mel and Enid Zuckerman Arizona College of Public Health, The University of Arizona Tucson, AZ USA
Search for more papers by this authorDouglas F. Larson
Sarver Heart Center College of Medicine The University of Arizona Tucson, AZ USA
Search for more papers by this authorFirst published: 30 August 2007
Summary
This chapter contains section titled:
-
Introduction
-
Heart failure
-
Inflammation and the metabolic syndrome
-
Inflammation and obesity
-
Inflammation and hyperglycemia
-
Acknowledgments
-
References
References
- Muhlestein JB Anderson JL Horne B. et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 2003; 146: 351–8.
- Nielson C Lange T. Blood glucose and Heart failure in nondiabetic patients. Diabetes Care 2005; 28: 607–11.
- The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999; 354: 617–21.
- Thrainsdottir IS Aspelund T Thorgeirsson G et al. The association between glucose abnormalities and Heart failure in the population-based Reykjavík study. Diabetes Care 2005; 28: 612–6.
- Nichols GA Hillier TA Erbey JR Brown J.B. Congestive Heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001; 24: 1614–9.
- Kamalesh M Nair G. Dirproportionate increase in prevalence of diabetes among patients with congestive Heart failure due to systolic dysfunction. Int J Cardiol 2005; 90: 125–7.
- De Groote P Lamblin N Mouquet F et al. Impact of diabetes mellitus on long-term survival in patients with congestive Heart failure. Eur Heart J 2004; 25: 656–62.
- Marwick T.H. Diabetic Heart disease. Heart 2006; 92: 296–300.
- Bell D.S. Heart failure: the frequent, forgotten and often fatal complication of diabetes. Diabetes Care 2003; 26: 2433–41.
- Anker SD von Haehling S. Inflammatory mediators in chronic Heart failure: an overview. Heart 2004; 90: 464–70.
- Matsumoto K Sera Y Abe Y Ueki Y Tominaga T Miyake S. Inflammation and insulin resistance are independently related to all-cause of death and cardiovascular events in Japanese patients with type 2 diabetes mellitus. Atherosclerosis 2003; 169: 317–21.
- Pickup JC Mattock MB Chusney GD Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286–92.
- Festa A D'Agostino R Jr, Howard G Mykkånen L Tracy RP Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 2000; 102: 42–7.
- Hunt SA Baker DW Chin M. et al. ACC/AHA Guidelines for the evaluation and management of chronic Heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee to revise the 1995 guidelines for the evaluation and management of Heart failure). Circulation 2001; 104: 2996–3007.
- Gutierrez C Blanchard D.G. Diastolic Heart failure: challenges of diagnosis and treatment. Am Fam Physician 2004; 69: 2609–16.
- Bell D.S. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease. Diabetes Care 2003; 18: 5708–14.
- Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97.
- Hu FB Stampfer MJ Haffner SM Solomon CG Willett WC Manson J.E. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25: 1129–34.
- Rutter, MK, Meigs, JB, Sullivan, LM, D'Agostina, RB, Wilson, PWF. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham offspring study. Circulation 2004; 110: 380–5.
- Sundström J Risěrus U Byberg L Zethelius B Lithell H Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 332, 878–882.
- Lemieux I Almeěras N Maurieěge P et al. Prevalence of “hypertriglyceridemic waist” in men who participated in the Queěbec Health Survey: association with atherogenic and diabetogenic metabolic risk factors. Can J Cardiol 2002; 18: 725–732.
- Kahn HS Valdez R. Metabolic risks identifiedbythe combination of enlarged waist and elevated triacylglycerol concentration. Am J Clin Nutr 2003; 78: 928–34.
- McNulty PH Luard RJ Deckelbaum LI Zaret BL Young L.H. Hyperinsulinemia inhibits myocardialprotein degradation in patients with cardiovascular disease and insulin resistance. Circulation 1995; 92: 2151–6.
- Phillips RA Krakoff LR Dunaif A Finegood DT Gorlin R Shimabukuro S. Relation among left ventricular mass, insulin resistance, and blood pressure in nonobese subjects. J Clin Endocrinol Metab 1998; 83: 4284–8.
- Kim J Koh KK Quon M.J. The union of vascular and metabolic actions of insulin in sickness and in health. Arterioscler Thromb Vasc Biol 2005; 46: 1978–85.
- Koh KK Han SH Quon M.J. Inflammatory markers and the metabolic syndrome. J Am Coll Cardiol 2005; 46: 1978–85.
- Pickup JC Mattock M.B. Activation of the innate immune system as a predictor of cardiovascular mortality in type 2 diabetes mellitus. Diabet Med 2003; 20: 723–6.
- Jarrett RJ Shipley M.J. Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease: putative as-sociationvia common antecedents; further evidence from the Whitehall study. Diabetalogia 1998; 31: 737–40.
- Fernandez-Real JM Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endoc Rev 2003; 24: 278–301.
- Trayhurn P Wood I.S. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 2005; 33: 1078–81.
- Arita Y Kihara S Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79–83.
- Mazurek T Zhang L Zalewski A et al. Human epicar-dial adipose tissue is a source of inflammatory mediators. Circulation 2003; 108: 2460–6.
- Young ME McNulty P Taegtmeyer H. Adaptation and maladaptation of the Heart in diabetes. Part II: Potential mechanisms. Circulation 2002; 105: 1861–70.
- Poirier P Bogaty P Garneau C Marois L Dumesnil J.G. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic car-diomyopathy. Diabetes Care 2001; 24: 5–10.
- Redfield MM Jcobsen SJ Burnett JC Mahoney DW Bailey KR Rodeheffer R.J. Burden of systolic and dias-tolic ventricular dysfunction in the community. JAMA 2003; 289: 194–202.
- Schannwell CM Schneppenheim M Perings S Plehn G Strauer B.E. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 2002; 98: 33–9.
- Devereux RB Roman MJ Paranicas M et al. Impact of diabetes on cardiac structure and function: the strong Heart study. Circulation 2000; 101: 2271–6.
- Stratton IM Adler AI Neil H.A. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–12.
- Palmiere V Tracy RP Roman M. et al. Relation of left ventricular hypertrophy to inflammation and albumin-uria in adults with type 2 diabetes. Diabetes Care 2003; 26: 2764–9.
- Boudina S Abel E.D. Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology 2005; 21: 250–8.
- Szabo C. PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News Perspectives 2002; 15: 197–205.
- Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813–20.
- Nourooz-Zadeh J Rahimi A Tajaddini-Sarmadi J et al. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia 1997; 40: 647–53.
- Petersen KF Dufour S Befroy D Garcia R Shulman G.I. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664–71.
- Hokama J Ritter LS Davis-Gorman G Cimetta AD Copeland JG McDonagh P.F. Diabetes enhances leukocyte accumulation in the coronary micr. Circulation early in reperfusion following ischemia. J Diabetes Complications 2000; 14 (2): 96–107.
- Freedman SF Hatchell D.L. Enhanced superoxide radical production by stimulated polymorphonuclear leukocytes in a cat model of diabetes. Exp Eye Res 1992; 55: 767–73.
- Wakasaki H Koya D Schoen, FJ et al. Targeted overexpres-sion of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci 1997; 94: 9320–5.
- Ishii H Jirousek MR Koya D et al. Amelioration of vascular dysfunction in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728–731.
- Inoguchi T Sonta T Tsubouchi H et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. JASN 2003; 14: S227–32.
- Lyle AN Griendling K.K. Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology 2006; 21: 269–80.
- Inoguchi T Battan R Handler E Sportsman JR Heath W King G.L. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and Heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci 1992; 89: 11059–63.
- Weber KT Brilla CG Campbell SE Zhou G Matsub-ara L Guarda E. Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press 1992; 1: 75–85.
- Craven PA Studer, RK, Negrete H DeRubertis F.R. Protein kinase C in diabetic nephropathy. J Diabetes Complications 1995; 9: 241–5.
- Bauters C Lamblin N McFadden EP Van Bell E Millaire A DeGroote P. Influence of diabetes mellitus on Heart failure risk and outcome. Cardiovas Diabetol 2003; 2: 1–16.
- Yan SF Ramasamy R Naka Y Schmidt A.M. Glycation, inflammation, and RAGE: a scaffold for the macrovas-cular complications of diabetes and beyond. Circ Res 2003; 93: 1159–69.
- Schmidt AM Yan SD Yan SF Stern D.M. The multi-ligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949–55.
- Chandra D Jackson EB Ramana1 KV Kelley R Srivastava1 SK Bhatnagar A. Nitric oxide prevents aldose reductase activation and sorbitol accumulation during diabetes. Invest Ophthalmol Vis Sci 1981: 314–26.
-
Honing MLH
Morrison PJ
Banga JD
Stroes ESG
Ra-belink T.J.
Nitric oxide availability in diabetes mellitus.
Diabetes/Metabolism Rev
1998;
14:
241–9.
10.1002/(SICI)1099-0895(1998090)14:3<241::AID-DMR216>3.0.CO;2-R CAS PubMed Web of Science® Google Scholar
- Cai H Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840–4.
- Consentino F Katusic Z. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 1995; 91: 139–44.
- Chung SM Ho ECM Lam KSK Chung S.K. Contribution of polyol pathway to diabetes-induced oxidative stress. JASN 2003; 14: S233–6.
- Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 1998; 50: 21–34.
- Williamson JR Chang K Frangos M et al. Hyper-glycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801–13.
- Ni C Hsieh H Chao Y Wang D.L. Interleukin-6-induced JAK2/STAT3 signaling pathway in endothelial cells is suppressed by hemodynamic flow. Am J Physiol 2004; 287: C771–80.
-
Modesti A
Bertolozzi I
Gamberi T et al.
Hyper-glycemia activates JAK2 signaling pathway in human failing myocytes via angiotensin II-mediated oxidative stress.
Diabetes
2005;
54:
294–401.
10.2337/diabetes.54.2.394 Google Scholar
- Hwang JC Shaw S Kaneko M Redd H Marrero MB Ramasamy R. Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury. FASEB J 2005; 19: 795–7.
- Tong PC Lee KF So W. et al. White blood cell count is associated with macro- and microvascular complications in Chinese patients with type 2 diabetes. Diabetes Care 2004; 27: 216–22.
- Tuttle HA Davis-Gorman G Goldman S Copeland JG McDonagh P.F. Platelet–neutrophil conjugate formation is increased in diabetic women with cardiovascular disease. Cardiovasc Diabetol 2003; 2: 1–16.
